The BioFire FilmArray respiratory panel is a multiplex PCR technology capable of detecting a number of bacteria and viruses that cause respiratory tract infection. The assay is technically simple to perform and provides rapid results, making it an appealing option for physicians and laboratorians. The initial product released by BioFire (version 1.6) was reported to have poor sensitivity for adenovirus detection and was therefore of concern when testing immunocompromised patients. This study evaluates the redesigned FilmArray assay (version 1.7) for detection of adenovirus. In this evaluation, we performed both retrospective and prospective verification studies, as well as a detailed serotype analysis. We found that version 1.7 demonstrated improved adenovirus sensitivity. In retrospective studies, sensitivity improved from 66.6% to 90.5%, and in prospective studies, it improved from 42.7% to 83.3%. In addition, when 39 clinically relevant serotypes were tested, 8 were not detected by version 1.6 and only 1 was not detected by version 1.7. The limit of detection remained the same when tested against serotype 4 but improved by 2 log units for serotype 7. Lastly, turnaround time analyses showed that the FilmArray assay was completed 3 h and 9 min after collection, which was more than a 37-h improvement over the previous multiplex PCR assay performed in our laboratory.
6 July 2014 in Journal of Cancer Research and Clinical Oncology
Background: Preoperative accurate visceral pleural infiltration (VPI) diagnosis for T1-size non-small cell lung cancer (NSCLC) is significant for clinical decision-making. The study aimed to explore the diagnostic efficacy of computed tomography (CT) imaging features and serum biomarkers in diagnosing VPI in newly discovered subpleural NSCLC ≤3 cm. Methods: There were 447 patients with NSCLC ≤3 cm retrospectively enrolled and assigned to the VPI group (n=81) and the non-VPI group (n=366) based on elastic fiber staining results. The serum biomarkers and CT imaging features were obtained for each subject. Univariate and multivariate analyses were used to identify the independent predictors for VPI. Area under the receiver operating characteristic (ROC) curve (AUC) was used to evaluate the diagnostic performance of each independent predictor and combined predictors in predicting VPI, with performance compared using the DeLong test. Results: For tumor biomarkers, the VPI group had a significantly higher percentage of cases with abnormal carcino-embryonic antigen (CEA) level, cytokeratin 19 fragment (CYFRA21-1) level, and pro-gastrin-releasing peptide (ProGRP) level than that of the non-VPI group (P<0.001, P=0.003, P=0.004). However, in multivariate analysis, only the lesion-pleura relationship patterns type Ia [odds ratio (OR) =20.689; 95% confidence interval (CI): 5.058–84.622; P<0.001], type Ib (OR =5.155; 95% CI: 1.178–22.552; P=0.03), type II (OR =7.154; 95% CI: 1.733–29.53; P=0.007) with type III as reference, solid lesion density (OR =9.954; 95% CI: 4.976–19.911; P<0.001) with part-solid density as reference were identified as the independent predictors for VPI. In predicting VPI, the combined model (AUC =0.885) significantly outperformed models based on lesion density (AUC =0.833) and lesion-pleura relationship patterns (AUC =0.655) (all P<0.001). Conclusions: The CT predictors for VPI in patients with subpleural NSCLC (≤3 cm) were lesion density and lesion-pleura relationship patterns (pleural attachment and indentation), but not serum tumor biomarkers.